In the 2026 China PIII, Zai Lab ranked 10th in Innovation and 5th in Invention, supported by its well-established international collaboration and commercialization system as well as deepening capabilities in global clinical development and in-house R&D. As one of the first Chinese innovative drug companies to establish a "global innovation + local development" model, Zai Lab is further expanding this path, continuously strengthening its pipeline through internal drug discovery and global-rights programs, and transforming from a company focused on development and commercialization in China toward a model in which "regional commercialization + global development + internal innovation" advance in synergy.

Zai Lab's competitive advantage lies not only in its ability to develop and translate global innovative medicines, but also in the commercial infrastructure of meaningful scale it has built, which supports the continued delivery of innovation...

Download the report to see the full company profile.